Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00123903 · ClinicalTrials.gov registry record · Phase 3
COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,220
- Enrollment target
NCT00123903 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 1,220 participants.
The verdict
NCT00123903, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,220 participants
- Enrollment target
Study Summary
This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.
Interventions
- DRUG lisinopril
- DRUG carvedilol MR
- DRUG metoprolol xl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,220 participants |
| Start Date | 2005-07 |
| Est. Completion | 2006-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00123903
The ClinicalTrials.gov registry entry for NCT00123903 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,220 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which lisinopril is the first listed.
NCT00123903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00123903 about?
NCT00123903 is a clinical study titled "COREG MR Versus TOPROL-XL On Reduction Of Microalbuminuria In Patients With Hypertension And Microalbuminuria". This study was designed to determine whether COREG MR is more effective than TOPROL-XL in reducing microalbuminuria in type 2 diabetic or non-diabetic patients with high blood pressure and microalbuminuria.
What is the current status of trial NCT00123903?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,220 participants. The study started on 2005-07. Estimated completion is 2006-05.
What interventions are being tested in trial NCT00123903?
The interventions under investigation include: lisinopril (DRUG), carvedilol MR (DRUG), metoprolol xl (DRUG).
Who is sponsoring clinical trial NCT00123903?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.